Christopher R. Reidy
Thanks, morning, everyone. and good Vince,
slide our highlights. X.X% results, key I'll first revenue first well a currency-neutral quarter to revenues on Total grew EPS as review on the approximately Moving billion X, as quarter financial and of basis. $X.X
strong. Vince As is performance our mentioned, underlying
company Our first approximately quarter points. total results growth dispensing U.S. by basis change, lowered include the from the impact which XXX revenue
drove declined Excluding XX we X.X%. growth approximately the points of in this about impact, basis first quarter. revenue Pricing
or the year growth a basis. was and change, prior more U.S. growth end color the for reflects tough growth you single-digits. the of Adjusted X.X% when results transaction, take X.X%, in I quarter on faced was change last upon the of EPS in currency-neutral closing the In and on I'll we geography. addition, our as a Adjusting expected. comparison U.S. the to you in this year. to Bard the to the times. in provide revenue $X.XX by the X.X EPS This we tough quarter of quarter, the as the strong communicated December, dispensing prior grew comparison dispensing moment leverage gross through At high segment debt X.X%
X to is years. previously line XXXX. delever our begin leverage This the we have what in of with times deleverage in timing and over We commitment expect latter three communicated below to half fiscal to
I'll a segment basis. X.X%, of X, includes our on to quarter Medical dispensing revenues by BD basis currency-neutral a approximately review which from the first slide revenue headwind U.S. XXX on Moving increased growth points change.
estimated growth strong MPS the faced our prevention points driven grew year. from tough change U.S. X% U.S. and continued or revenue Segment on revenues Medication in the basis. X% by Procedural of in XXX quarter. of surgical the underlying Revenue declined basis the impact a the in was infection points comparison to Revenues Growth Solutions dispensing Management the pre-filled in the X.X%. first Medical Solutions basis over tough an In products. approximately of in comparison, BD dispensing combined MMS flush the from and by Medication headwind prior impacted strength for the XXX and particular Medical the or first quarter grew addition, growth the change. Segment was devices, Adjusting
of in in grew timing in reflects and change the the XX%. growth Systems, orders. growth tough to for year and in approximately impact in grew the U.S. of Adjusting of timing In the year MMS pen XX.X% tough customer dispensing prior X.X% timing by was infusion by resulted year addition, quarter aided In revenues comparison prior capital of XXX Pharmaceutical despite where to growth tough of MMS a estimated where where combined prior the grew U.S. X.X% installations the the first was of the by the the revenues comparison tough in revenues the both aided Care This basis needles. comparison, dispensing Diabetes grew X.X%, the orders. prior in from points year driven a comparison X%. customer
turning XX Now, BD Life and Sciences to slide Segment. the
First early Strength the contributed increased an estimated XX year, Life comparison was season segment Sciences growth. aided points quarter an which basis by flu revenues across X.X%. to last in to
the severity BD continued strong installations the the in season well as by flu Europe. EMA, in XX.X% of and was our as you're impact molecular quarter. can and and strength core timing driven As in timing microbiology growth Performance Revenues in grew Systems aware, the Diagnostic our platform of MAX comparisons. year-over-year in Kiestra U.S.,
instruments the Diagnostic to of growth The contributed as X.X% FACSMelody reflects as continued core strong earlier flu strength Biosciences the the Systems momentum of as growth the research grew XXXX Systems revenues second and was quarter. newer This expected. XXX reagents. as points products. in half research in from the basis such by X% FACSymphony continued an addition, In growth our well in quarter. driven Preanalytical strength in season estimated in
which you prior the was Sciences Systems prevention. in MPS units reflects mentioned by Growth well and to BD driven and in estimated basis. moving in revenues U.S. MPS change. year strong prior points first in revenues on the to dispensing products. the infection growth to basis the U.S. infusion-related in in strength season driven health women's as Now, previously Preanalytical and the currency-neutral the Diagnostic MMS Diabetes in X.X% from flu and in Growth growth the of U.S. I'll tough in Systems the in U.S. was as across XX, performance Medical earlier comparisons the an newer Preanalytical also slide Systems first MAX Systems U.S. growth disposables Care revenue strength the our in the Life Diagnostic continued was Growth by by driven includes assays. for comparison by impacted our a quarter, in unit Segment. XXX core year walk quarter headwind The the Segment geographic grew the through driven in
strength Pharmaceutical and MPS to core Systems, change and first the quarter. of U.S. in strong installations points. on strong revenues Diagnostic moving was Now, aided XXX X.X% markets Biosciences geographic research devices and was first instruments international, Diagnostic contributed by patterns, the which in grew Growth newer performance driven headwind sales and pre-filled quarter, flush by our Systems. international estimated including growth from in Strength grew was our in and revenues by unit. markets in microbiology growth. an within in clinical Growth the X.X% in within Kiestra Developed in ordering Europe strong developed in to Systems also basis driven dispensing of Systems Pharmaceutical
markets X% by the China EMA tenders. grew was timing of of of double-digit emerging aided by growth XX%, that revenues quarter growth driven in First and
results. statement income currency-neutral to recaps quarter turning first XX Now, and highlights our slide which the
As discussed, points U.S. revenues includes dispensing X.X% negative quarter, change. basis approximately in from grew impact the the which XXX
was XX.X%, P&L, profit starting an to loss the increase details is change, despite of provide gross in profit of which margin year-over-year. was related profit moment. dispensing the gross profit, down SSG&A of a I'll revenues percentage a with the just U.S. a strong very gross as additional on Moving X.X% gross XX.X%.
first in September, on to efforts shipping we scale our related shipments costs quarter. additional we to As as late last in incurred the call. discussed expected, our earnings
with pleased the getting tough revenues continued change the to an results increase and X.X%, underlying a comparison leverage year. we're in well which as in U.S. dispensing as our a of of innovation. include prior X% percentage also of invest commitment in the the basis, Our as we're SSG&A. reflects R&D dollars R&D a was impact very On year-over-year
of year. earnings and negative Our income grew declined approximately U.S. per XXX quarter. Operating the XX.X% points grew the include income tax prior share X.X%, the and to compared adjusted to rate change. operating EPS from X.X% dispensing Both in impact basis
the Now, turning margins and slide profit our and to XX gross operating first for quarter.
U.S. out dispensing XX declined performance points mentioned, XX gross very synergies I basis driven by points improved mix pricing, had On margin from materials, a the As positive basis offset initiatives, the profit cost of increase and gross margin. a in headwind by was partially a offset SSG&A margin from quarter. of profit points margin guidance you by is profit and Operating XX inclusive margin the were This Currency points impact discussed, a significant points raw basis as favorable basis BD. an points, inclusion first I'll partially basis, expansion our I'd improvement next in strong of of guidance but was take the to previously gross we're impact margin XX.X% year, of change. quarter. Bard in by basis company the the for second on basis in points of to XX from currency. a points of positive as beginning XX continuous XXX over several to and full expect that fiscal XXX prior approximately quarter like for of of through points. Bard of discussing basis reflects slides, basis combined expansion legacy XXXX underlying to increase point XXX the while XXX we margins, the XXX deliver This basis the
deliver period year four-year XXXX, the we margin of expansion. approximately fiscal XXX basis points expect to Over through
call, in impact X% the our guidance X.X% which XXXX Moving estimated slide to Bard growth XX-basis-point excluding November the acquisition, a currency-neutral an revenue on change. X.X%, our strong on Prior XX we X% closing for guidance. of basis, fiscal earnings represented to dispensing of from U.S. full to revenue BD on standalone underlying growth provided year to
XX X% XXX-basis-point in from that X% Hurricane a on estimated growth Rico results standalone expected X%. of Bard's XXXX. quarter in This an to on represents adverse the basis, on Maria revenues December grow Now, underlying basis, to X% strong Bard's excludes are Puerto ended to impact an of which
revenues expect related do hurricane. we the impact forward, to not Bard's an Going to
earnings you'll On reflect in impact we Maria provided the on BD any Hurricane not side, November as EPS fiscal guidance adverse year Rico. XXXX potential our to the recall, revenue and did call Puerto related
time, of efforts call, November quicker had back up than Subsequent corresponding thanks our impact our revenues many that we $XX a to in able were could our anticipated. of estimated million impact EPS However, to we heroic to up associates, growth. previously online of the at to to of be get with X-percent-point plans the
impact our fiscal result, and now to has revenues includes and XXXX hurricane. a the EPS As related impact minimized the for been current non-material to year a guidance
completed Bard For a current the of Bard, the periods plus revenue with new strong currency-neutral if that to acquisition of BD beginning we the and year growth the growth X% we announcement. year. the BD and basis comparable expect This X.X% deal communicating been since both expectations represents the our line at X% to and fiscal on prior of been had have underlying includes is in XXXX in as X.X%
revenue segment our in you'll XX our slide to segments. guidance, three guidance see Turning for
realigned with BD the products analogous BD has the in certain not Medical been and BD between Interventional result, movement have resulted new a a of our as the BD market Bard strategy. This Segment legacy As with go and Interventional is Bard. revenues legacy and reminder, Segments, Medical to
We expect to and X% BD between X%. grow Medical
excluding in We the expect increase our to Hurricane between X.X% impact Interventional the expect grow Puerto BD that guidance. between XXXX. Segment and Segment is and Maria our Sciences ended X.X% December X.X%, new Life And in the grow X.X% prior to an we which XX, from Rico from quarter
from fiscal strength a the we to in The we and in of in growth low Bard X.X% and estimated mid-teens and result, around base markets, and a and X% and Puerto the hurricane both and in by product markets dispensing We around Rico. EMA across developed accelerates in anticipate XX-basis-point or excluding of XXXX America. developed impact strength combination our expect and China growth three both U.S. now in emerging developed growth launches market revenue by now driven with emerging double-digit Latin as profile the change diversified emerging growth driven growth expect be In markets. all recent segments BD
some a year. moment quarter results their we'd the provide For to to represented on take color XX, of quarter fourth ended for XXXX Bard's the transparency, which December that like fiscal
of to the revenue share X.X% of a the growth key hurricane, impact basis on Revenue the in some we driven quarter. quarter China America in company's adverse revenues the and do an at guidance. wanted with emerging more our line performance and Bard's guidance. the discuss growth included continued strength into which Latin plan to Maria the across length, not revenues performance markets. were in and results and Bard's by Bard grew Puerto While for XXX we points in quarter business basis, fourth insights prior in line Adjusting X%, with from Rico. approximately Bard's earnings was currency-neutral was in Hurricane prior broadly December expectations
In in addition, the AV. Lutonix launch aided Vascular Peripheral of in strong high single-digit was the by growth U.S.
a on reported BD's forward. number our There new fiscal moving a parts reporting guidance. XX to impact these per As EPS in full And share XXXX. businesses fiscal moving slide in going of XXXX structure that will reminder, be and are earnings year
growth to change from $XX.XX income, XX%, X% Starting we color purposes ensure and chart, call modeling EPS our on operating to provided approximately rate. driven the expected November of offset tax X% to on guidance. X% with approximately reflected the headwinds from I'd we increase the and adjusted in like effective provide side partially left for U.S. of $XX.XX. the by guidance of more dispensing to EPS legacy in our For BD, by consistency, This earnings expected on currency-neutral strong of growth an
expected provide expected tailwind resulting growth currency in XXXX in EPS XX%. in time, place would currency a we X% of rates approximately fiscal foreign Assuming the at
and result drainage the is low line tunneled, acquisition a accretion Bard catheters in of X% the the by product line of net we expect core Bard's communicating. needle with single-digit of right X% The Bard biopsy well to chart, of X%. from is of underlying been close home Aspira as the soft to our tissue timing accretion, expected line to what combination continuing the and be offset we've accessories, divestitures from This product is as of the which in acquisition. approximately Now,
and in is of guidance combined tax and to approximately previously the from results tax From tax As of million a through our detailed toward earnings that expect synergies with P&L an you'll to X% to approximately increase plan is reform this an our of XX% driven by see invest XX% effective primarily when take an by decrease next rate of had revenue guidance. U.S. slide, consistent XXXX. the I approximately X% we rate This you investment on effective in we to basis is XX% standpoint, we our fiscal communicated Bard initial thoughts, dilutive approximately XX and $XX to EPS points. XX%
we've our does EPS This an flu, basis while in related U.S. that we're of in you growth resin pricing items the announcement. with to line XX% XX% the related for addition, is mid-teens XX% profile guidance expected been dispensing In in the since is change. underlying these the an impact increase net offsetting XXXX adjusted the fiscal approximately to also or communicating deal to growth The on benefit. from flu pressure seeing anticipate results the adjusted increased to currency-neutral
a dollar exchange XXX incremental in about currency euro rate newco $X.XX. which to of rates. All-in, This XX% to earnings represents growth. an anticipate of we $XX.XX to $XX, Lastly, this current based results points assumes basis strong XX% of tailwind on
in years cost year single-digit year fiscal a exit single-digit in expect million the million we deliver fairly element XXXX. committed year expect in XXXX, of balance phasing while note accretion in to XXXX fiscal ratable reaffirming are fiscal being $XXX and cost to XXXX. we annualized $XX From to fiscal We're fiscal important fully XXXX, synergies $XX guidance our realizing XXXX. we achieve million we to with that synergies perspective, year Another high is as in low over accretion to
our guidance fiscal the This Turning Bard guidance X, like you beginning results for new the the the BD balance full expectations Bard. year of XX, fiscal our I'd XXXX is including includes to quarter. as of of for slide January walk second through of to XXXX, the which
BD by of reported the We of our to revenue expect XX% to a a revenue increase be XX.X% driven XX%. SSG&A an inclusion for is of of robust gross is which to is includes basis approach, guidance points. expected to expected tailwind XX%, be is approximately approximately due XX% This due is profile. spend standalone November G&A and gross our cost to increase synergies. newco the guidance growth is XXX SSG&A of Adjusted compared Bard's anticipated points Adjusted direct from which This approximately sales. profit XX.X% for related currency Bard's to of profile to is and to margin higher standalone basis an as BD percentage primarily XXX partially sales by prior offset
R&D to X% at We in our to line year expect with X% XXXX investments of fiscal be revenues.
new a and new will platforms. As products invest continue to we in company,
just I fiscal is On of the basis, items the XX% of to XX% by result basis and to margin underlying operating a points to our we XXX year. expected between XXX for be currency-neutral expect detailed, total operating points revenues. basis improve As a margin
between and XX% our we discussed, As tax to we XX%. be rate expect
expected anticipate average be XXXX. $XXX fiscal adjusted shares. approximately be our flow flow diluted to XXXX, expected with to is XXX about between $XXX be strong billion we Capital million. fully $X.X and For million expenditures million Cash of operating count are fiscal cash year share year to in
what to have the BD in we been able are excited confident you about be the to commitments we'll we've the year our on and So announcement of since the in that transaction. consistent and I'm I'm businesses XXXX, with communicating fiscal Bard across deliver summary, which strong momentum
provide to you initiatives turn portfolio. and Now, over to like with on Vince I'd update our an the back product key call who'll
